Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Self- versus Conventional Management of Oral Anticoagulant Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term prognosis following hospitalization for acute myocarditis - a matched nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

An increased risk of cardiovascular disease (CVD) has been observed in a range of chronic inflammatory diseases (CID), including rheumatoid arthritis (RA), psoriasis, inflammatory bowel diseases (IBD), and systemic lupus erythematosus (SLE). The increased risk of CVDs and reduced life expectancy in these conditions has stimulated considerable research and started an ongoing discussion on the need for a multidisciplinary approach and dedicated guidelines on CVD prevention in these patients. In addition, the possibility of inhibiting inflammation as a means to preventing CVD in these patients has gained considerable interest in recent years. We briefly summarize the current level of evidence of the association between CIDs and CVD and cardiovascular risk management recommendations. Perspectives of ongoing and planned trials are discussed in consideration of potential ways to improve primary and secondary CVD prevention in patients with CID.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Cardiovascular Drugs
Vol/bind16
Udgave nummer1
Sider (fra-til)1-8
DOI
StatusUdgivet - feb. 2016

ID: 45868982